Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) shares traded up 4.8% during trading on Tuesday . The company traded as high as C$4.63 and last traded at C$4.38. 31,105 shares changed hands during mid-day trading, an increase of 96% from the average session volume of 15,840 shares. The stock had previously closed at C$4.60.
A number of research analysts recently commented on the company. TD Securities reduced their target price on Cipher Pharmaceuticals from C$6.50 to C$5.00 and set a “hold” rating on the stock in a research note on Tuesday, November 7th. Bloom Burton cut Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 14th.
In related news, Director Harold Morton Wolkin acquired 35,000 shares of Cipher Pharmaceuticals stock in a transaction dated Friday, November 10th. The shares were purchased at an average cost of C$4.69 per share, with a total value of C$164,150.00.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/11/14/cipher-pharmaceuticals-inc-cph-trading-up-4-8.html.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.
Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.